German drug company Evotec has signed up for a major expansion of its office and laboratory space at Milton Park, making it one of the largest occupiers there.

The firm has taken 43,141 sq ft across three floors at 95 Park Drive in addition to the 16,823 sq ft at 90 Park Drive it took in September 2020.

Evotec has had a presence at Milton Park since it merged with Oxford Asymmetry International in 2000. Oxford Asymmetry International had been based at Milton Park since 1989.

Christophe Muller, head of Evotec’s Milton Park site, said: “We are proud to be growing our Milton Park presence into the fully integrated, co-located drug discovery and development centre we now call Dorothy Crowfoot Hodgkin Campus.

“Ninety-five Park Drive gives us the high-quality space we need to further strengthen our biology capabilities and expertise on site, bringing together all the key functions required to provide an accelerated path for our partners from discovery to commercial manufacture.”

Philip Campbell, commercial director, MEPC commercial director, Milton Park said: “95 Park Drive is a prominent building which will provide Evotec with much-needed new office and lab space as they continue their impressive growth plans. We continue to see strong demand from the global health and life sciences sectors looking to be based in Oxfordshire for satellite, expansion or relocation space.”

© Thames Tap (powered by

Sign up to receive your free weekly Thames Tap newsletter here.